

WHAT IS CLAIMED IS:

- ~~1. An oligonucleotide for targeted alteration(s) of genetic sequence, comprising a single-stranded oligonucleotide having a DNA domain, said DNA domain having at least one mismatch with respect to the genetic sequence to be altered, and further comprising chemical modifications within the oligonucleotide, said targeted alteration(s) occurring more frequently than alteration(s) of the genetic sequence by a double-stranded double hairpin chimeric oligonucleotide containing RNA and DNA nucleotides.~~
- ~~2. The oligonucleotide according to claim one that comprises at least one phosphorothioate linkage within the oligonucleotide.~~
- ~~3. The oligonucleotide according to claim one that comprises a 2'-O-methyl analog.~~
- ~~4. The oligonucleotide according to claim one that comprises a locked nucleotide analog.~~
- ~~5. The oligonucleotide according to claim one that comprises a combination of at least two modifications selected from the group of a phosphorothioate linkage, a 2'-O-methyl analog, a locked nucleotide analog and a ribonucleotide.~~
- ~~6. The oligonucleotide according to any one of claims 1 to 5 that comprises at least one unmodified ribonucleotide.~~
- ~~7. The oligonucleotide according to any one of claims 1 to 6, wherein the sequence of said oligonucleotide is selected from the group consisting of SEQ ID NOS: 1-4339.~~
- ~~8. A method of targeted alteration of genetic material, comprising combining the target genetic material with an oligonucleotide according to any one of claims 1 to 7 in the presence of purified proteins.~~

9. A method of targeted alteration of genetic material, comprising administering to a cell extract an oligonucleotide of any one of claims 1 to 7.

10. A method of targeted alteration of genetic material, comprising administering to a cell an oligonucleotide of any one of claims 1 to 7.

11. A method of targeted alteration of genetic sequence in a subject, comprising administering to the subject an oligonucleotide of any one of claims 1 to 7.

12. A method of targeted alteration of genetic sequence, comprising combining target genetic material with an oligonucleotide according to any one of claims 1 to 7, said target genetic material being a non-transcribed DNA strand of a duplex DNA.

13. The genetic material obtained by any one of the methods of claim 8, 9 or claim 10.

14. A cell comprising the genetic material of claim 13.

15. A non-human organism comprising the cell according to claim 14.

16. A pharmaceutical composition comprising the oligonucleotide according to any one of claims 1 to 7.

17. A method of targeted chromosomal genomic alteration, comprising administering the pharmaceutical composition of claim 16 to a subject.

18. A non-human organism produced by the method of claim 11 or claim 17.

19. A method of optimizing an oligonucleotide for targeted alteration of a genetic sequence, which comprises:

(a) comparing the efficiency of alteration of a targeted genetic sequence by an oligonucleotide of any one of claims 1 to 7 with the efficiency of alteration of the same targeted genetic sequence by a

second oligonucleotide, said second oligonucleotide selected from the group of (1) an oligonucleotide that is fully complementary to the target and lacks the mismatch, (2) a fully modified phosphorothiolated oligonucleotide, (3) a fully modified 2'-O-methylated oligonucleotide and (4) a chimeric double-stranded double hairpin containing RNA and DNA nucleotides.

20. The method of claim 19 in which the alteration is produced in a cell extract.

21. The method of claim 20 in which the cell extract is selected from the group of a fungal cell extract, a plant cell extract, a rodent cell extract, a primate cell extract and a human cell extract.

22. The method of claim 19 in which the alteration is produced in a cell.

23. The method of claim 21 in which the cell is selected from the group of a fungal cell, a plant cell, a rodent cell, a primate cell and a human cell.

24. A kit comprising the oligonucleotide according to any one of claims 1 to 7 and a second oligonucleotide selected from the group of (1) an oligonucleotide that is fully complementary to the target and lacks the mismatch, (2) a fully modified phosphorothiolated oligonucleotide, (3) a fully modified 2'-O-methylated oligonucleotide and (4) a chimeric double stranded double hairpin containing RNA and DNA nucleotides.

A
C